Short Interest in Biomerica, Inc. (NASDAQ:BMRA) Declines By 26.0%

Biomerica, Inc. (NASDAQ:BMRA) saw a significant drop in short interest in the month of March. As of March 13th, there was short interest totaling 45,117 shares, a drop of 26.0% from the February 26th total of 60,973 shares. Approximately 1.8% of the company’s stock are short sold. Based on an average daily volume of 19,526 shares, the short-interest ratio is currently 2.3 days.

Institutional Trading of Biomerica

An institutional investor recently raised its position in Biomerica stock. DRW Securities LLC lifted its holdings in shares of Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,925 shares of the company’s stock after acquiring an additional 6,533 shares during the quarter. DRW Securities LLC owned 0.56% of Biomerica worth $43,000 as of its most recent filing with the SEC. Institutional investors own 22.28% of the company’s stock.

Biomerica Trading Down 4.7%

NASDAQ BMRA opened at $2.01 on Friday. The stock has a market cap of $6.07 million, a P/E ratio of -2.16 and a beta of 0.21. The company’s fifty day simple moving average is $2.21 and its 200-day simple moving average is $2.50. Biomerica has a 52 week low of $1.87 and a 52 week high of $5.12.

Biomerica (NASDAQ:BMRA) last released its quarterly earnings results on Wednesday, January 14th. The company reported ($0.45) earnings per share for the quarter. Biomerica had a negative net margin of 90.29% and a negative return on equity of 83.73%. The firm had revenue of $1.21 million for the quarter.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.